RIGL FY 2020 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$517M

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$109M+83.2% YoY

Gross Profit

$108M99.2% margin

Operating Income

-$29M-26.7% margin

Net Income

-$30M-27.4% margin

EPS (Diluted)

$-1.80

Cash Flow

Operating Cash Flow

-$52M

Free Cash Flow

-$53M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$110M

Total Liabilities

$76M

Stockholders' Equity

$34M

Cash & Equivalents

$30M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$109M	$59M	+83.2%
Gross Profit	$108M	$58M	+84.5%
Operating Income	-$29M	-$69M	+58.1%
Net Income	-$30M	-$67M	+55.3%